Non-insulin Therapies for Diabetes Market: Regional Insights
On the basis of region, the
global Non-Insulin
Therapies for Diabetes Market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America is
expected to drive growth of the non-insulin therapies for diabetes market due
to highest diabetes expenditure in the U.S. According to the International
Diabetes Federation (IDF), in 2017, around 17,100 new cases of diabetes were
detected in the U.S. Asia Pacific is one of the most lucrative region due to increased
diabetes burden in China and India, collectively having over 180 million
patients suffering from diabetes. According to the American Diabetes
Association (ADA), rising incidence of type 2 diabetes in South Asia is likely
to be over 150% between 2000 and 2035.
Non-insulin therapies are mostly
used in type 2 diabetes patients, where body either does not produce enough
insulin or is unable to effectively use the insulin it produces.
Non-insulin-based medication works with different mechanism of action to reduce
blood glucose level and maintain it for optimum glycemic control. For instance,
some agents increase the insulin release from pancreatic cells (Sulfonylureas),
some agents increase glucose uptake by periphery and reduces hepatic glucose
output (Biguanides), some agents slow down digestion of starch in small
intestine (alpha glucosidase inhibitors), and some medication reduces post meal
sugar by blocking certain enzymes (Incretin mimetics).
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2042
Non-Insulin Therapies for
Diabetes Market Dynamics
Increasing global incidence and
prevalence of diabetes is expected to fuel growth of the non-insulin therapies
for diabetes market. Non-insulin therapies are mainly used in type 2 diabetes,
which accounts for around 90% of the global diabetes cases. According to the
International Diabetes Federation’s (IDF) Diabetes Atlas 2017, worldwide
prevalence of diabetic patients was around 425 million, of which around 400
million patients were suffering from type 2 diabetes. As per the World Health
Organization (WHO) 2017 report, diabetes is one of the top 3 causes of death
among non-communicable diseases worldwide, with 114.4 million cases in China,
72.9 million cases in India, and 30.2 million cases in the U.S.
The global economic burden of
diabetes is high and is expected to substantially increase over the forecast
period. According to the American Diabetes Association research in March 2018,
the total costs of diagnosed diabetes have risen to US$ 327 billion in 2017
from US$ 245 billion in 2012. Therefore, non-insulin therapies for diabetes
market is expected to witness growth in the near future.
Moreover, companies are launching
new products and combination therapies in the market, which is expected to
drive growth of the global non-insulin therapies for diabetes market. For
instance, in 2017, the Food and Drug Administration (FDA) approved Novo
Nordisk’s Ozempic (semiglutide), which is once a week GLP-1 analog, would increase
the patient compliance. In December 2017, FDA approved the sodium-glucose
co-transporter 2 (SGLT2) inhibitor called ertugliflozin (Steglatro), which is
jointly developed by the Merck & Co. and Pfizer Inc. and in January 2018,
the European Medicines Agency (EMA) granted approval for the same in Europe.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/non-insulin-therapies-for-diabetes-market-2042
However, high cost of newer class
of drugs when compared to the conventional drugs are expected to negatively
impact the non-insulin therapies for diabetes market growth, especially in
regions such as South Asia, where there is large number of patients suffering
from type 2 diabetes. For instance, GLP-1 analog costs around US$ 492 for 30
day therapy, whereas Biguanides and sulfonylureas costs around US$ 5-9 for 30
day therapy.
Non-insulin Therapies for Diabetes
Market: Competitive Landscape
Key players operating in the
global non-insulin therapies for diabetes market include AstraZeneca,
Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Eli Lilly and Company,
GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Merck and
Company, Novartis AG, Novo Nordisk, Pfizer, Sanofi Aventis, and Takeda
Pharmaceuticals.
Major players are increasingly
targeting the newer class of drugs such as GLP-1 analogs or SGLT2. SGLT 2
inhibitors have been approved for use, as a treatment for diabetes since 2013.
Most of the drugs under SGL2 inhibitors such as Dapagliflozin, Canagliflozin,
and Empagliflozin were launched after 2013. However, intense competition in the
market could make it difficult for one particular company to grab larger market
share in the non-insulin therapies for diabetes market.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2042
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment